Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings

In this diagnostic study, a 12-lead (12L) ECG measurement was compared to KardiaMobile 6L in a tuberculosis trial. Performed in South Africa, the study assessed 191 participants. Triplicate reference standard 12L ECG results were human calibrated with readers blinded to 6L ECG results.

The handheld 6L device had a high negative predictive value of 99.8%.

This study suggests that simplified, handheld 6-lead ECG devices are effective triage tests that could reduce the need to perform 12L ECG monitoring in resource-constrained settings.

Key Takeaways:

KardiaMobile 6L is 99.8% accurate
The device could reduce the need to perform 12L ECG monitoring in resource-limited settings
There is proven diagnostic accuracy, repeatability, and feasibility with the 6L ECG device

Read Full Article

The Broad Impact of QT Monitoring: Extending Beyond Cardiac Health into Diverse Conditions

Beyond its traditional focus on cardiac-specific therapies, every investigational drug can potentially impact cardiac function. What if we expanded QT monitoring across various therapeutic areas?

KardiaMobile® 6L Versus 12-lead ECG: Effects on Clinic Utilization Time

Wiley.com | Clinic utilization time is significantly reduced with the KardiaMobile® 6L compared to traditional 12L ECG systems. This study published in Wiley highlights how the 6L minimizes the need for frequent conventional 12L use.

Remote Monitoring and Data Collection for Decentralized Clinical Trials

JAMAnetwork.com | Patient-centric trials require accessible digital health technologies. A JAMA study explores the current state and aspired role of remote monitoring and data collection tools in oncology trials.